What does this research mean for the field?

At 5-year follow-up, there is no significant difference in target lesion failure (TLF) between patients treated with the Polymer-Free Biolimus-Coated BioFreedom Stent and those treated with the Biodegradable-Polymer Sirolimus-Eluting Orsiro Stent in acute coronary syndrome (ACS) patients. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research examines long-term outcomes of two stent types in patients with acute coronary syndromes (ACS).

March 12, 2026

Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes

Key Result

At 5-year follow-up, target lesion failure did not differ significantly between patients treated with BioFreedom stents and Orsiro stents in acute coronary syndrome.

Key Points

This research examines long-term outcomes of two stent types in patients with acute coronary syndromes (ACS).
Follow-up conducted over 5 years
Comparison between polymer-free biolimus-coated stents and biodegradable-polymer sirolimus-eluting stents
Assessment of target lesion failure (TLF) and target lesion revascularization (TLR) rates
No significant difference in target lesion failure between stents at 5-year follow-up
Early increased risk of target lesion revascularization in STEMI patients with biolimus-coated stents did not persist after 5 years

Structured PICO

Does PCI with a polymer-free biolimus-coated stent reduce target lesion failure compared to a biodegradable-polymer sirolimus-eluting stent in patients with acute coronary syndromes?

Population

Patients with Acute Coronary Syndromes (ACS), including a subgroup of STEMI patients

Intervention

Percutaneous Coronary Intervention (PCI) with the polymer-free biolimus-coated stent (BioFreedom)

Comparator

Percutaneous Coronary Intervention (PCI) with the biodegradable-polymer sirolimus-eluting stent (Orsiro)

Outcome

Target Lesion Failure (TLF) at 5-year follow-upcomposite

Long-term (5-year) outcomes show no significant difference in target lesion failure between polymer-free biolimus-coated and biodegradable-polymer sirolimus-eluting stents in ACS patients.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

At 5-year follow-up, TLF did not differ significantly in BF-BCS or O-SES treated ACS patients. The increased risk of early TLR in STEMI patients treated with BF-BCS was not maintained at 5-year follow-up.

Bookmark

Cite This Study

Noori et al. (Mon,) reported a other. At 5-year follow-up, target lesion failure did not differ significantly between patients treated with BioFreedom stents and Orsiro stents in acute coronary syndrome.

synapsesocial.com/papers/69b25b4996eeacc4fcec9cd5 https://doi.org/https://doi.org/10.1002/ccd.70549

Bookmark